An observational study in Urinary Bladder Neoplasms, sponsored by Janssen-Cilag Farmaceutica Ltda.. Recruiting at 1 site in Portugal. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-28.
Sponsored by Janssen-Cilag Farmaceutica Ltda. (part of Johnson & Johnson) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Urinary Bladder Neoplasms by Johnson & Johnson — 2 open to participants now, 5 under way, 2 of them phase 3. Urinary Bladder Neoplasms · Johnson & Johnson.
Among the 12 studies in Urinary Bladder Neoplasms by Johnson & Johnson, this one is one of 2 that started in 2026, is one of 2 observational ones, and was the 12th registered.
1,800 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.
Browse Urinary Bladder Neoplasms studies →2 of the 12 studies in Urinary Bladder Neoplasms by Johnson & Johnson are open now, in 2 countries. Recruiting first, the newest first:
Janssen Korea, Ltd., Korea · Sites in Korea, Republic of
Ages 18+
By country, each count listing its studies:
Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 250 is above the median of 200 across 412 observational studies indexed under Urinary Bladder Neoplasms.
Median enrollment 71 across the 10 interventional studies, 126 across the 2 observational. Of the 7 that completed or were terminated, 2 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Janssen-Cilag Farmaceutica Ltda., one of the names counted as Johnson & Johnson. Under that name alone:
Janssen-Cilag Farmaceutica Ltda. is the lead sponsor of 13 studies on the registry; 2 are open to participants now.
2 of the studies in Urinary Bladder Neoplasms by Johnson & Johnson that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04658862Phase 3Janssen Research & Development, LLCA Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder | 2026-12-30 |
| NCT07735793Janssen Korea, Ltd., KoreaA Real-world Study in Participants With High-risk Non-Muscle-Invasive Bladder Cancer After Bacillus Calmette-Guérin Therapy in Korea | 2026-11-23 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies in Urinary Bladder Neoplasms by Johnson & Johnson, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to understand how the participants with high-risk non-muscle invasive bladder cancer are diagnosed, treated, and cared for in regular clinical practice in Portugal. HR-NMIBC is an early-stage bladder cancer that is limited to the inner lining of bladder but has a considerable high chance of cancer coming back or worsening.
The study population includes the participants from Portuguese hospitals that treat and manage High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) in routine clinical practice.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Participants diagnosed with high-risk non-muscle-Invasive bladder cancer (HR-NMIBC) in Portugal between January 1, 2016 and December 31, 2020, with tumor stage N0/x and M0/x and one of the following: Tis (primary CIS), TaG3/HG, or T1 will be enrolled. Demographic and clinical information will be gathered from both electronic and paper records for each participant. Only data available within routine clinical practice from the diagnosis until, at least, 5 years after diagnosis will be collected in this study. No drug will be administered as a part of this study.
Treatment Patterns: Type of Therapeutic Approach
Number of participants receiving different types of therapeutic approach including bacillus calmette-guerin (BCG) therapy, chemotherapy, radiotherapy, immunotherapy, or targeted therapy will be reported.
Time frame: Up to 5 years
Treatment Patterns: Type of Surgery
Number of participants undergoing different types of surgery, including transurethral resection of the bladder tumor (TURBT), repeat TURBT or cystectomy will be reported.
Time frame: Up to 5 years
Treatment Patterns by Subpopulation: Tumor Stage
Number of participants by tumor stage will be reported.
Time frame: Up to 5 years
Treatment Patterns by Subpopulation: Histology
Number of participants by histology will be reported.
Time frame: Up to 5 years
Treatment Patterns by Subpopulation: Line of Therapy
Number of participants by line of therapy will be reported,
Time frame: Up to 5 years
Total Number of BCG Doses Administered
Total number of BCG doses administered will be reported.
Time frame: Up to 5 years
Percentage of Participants With BCG Non-Responsive Disease
Percentage of participants with BCG non-responsive disease will be reported. This is defined as being one of the following: a) Persistent or recurrent carcinoma in situ (CIS) alone or with recurrent Ta/T1 (noninvasive papillary disease/tumor invades the subepithelial connective tissue) disease within 12 months of completion of adequate BCG therapy (defined as at least 5 of 6 induction doses, plus at least 2 of 3 maintenance doses or a second induction). b) Recurrent high-grade Ta/T1 disease within 6 months of completion of adequate BCG therapy. c) T1 high-grade disease at the first evaluation following an induction BCG course.
Time frame: Up to 5 years
Reasons for BCG Interruption
Number of participants with reasons for BCG interruption will be reported.
Time frame: Up to 5 years
Therapy Choice at Recurrence
Therapy choice at recurrence for participants will be reported.
Time frame: Up to 5 years
Recurrence-Free Survival (RFS)
RFS is defined as the time from the date of first treatment initiation for high-risk non-muscle invasive bladder cancer (HR-NMIBC) to the first documented recurrence of high-risk disease, death due to any cause, or censoring, whichever occurs first.
Time frame: Up to 5 years
Progression-Free Survival (PFS)
PFS is defined as the time from the date of first treatment initiation for HR-NMIBC to the first documentation of disease progression, death from any cause, or censoring, whichever occurs first.
Time frame: Up to 5 years
Overall Survival (OS)
OS is defined as the time from the date of first treatment initiation for HR-NMIBC to death from any cause or censoring, whichever occurs first.
Time frame: Up to 5 years
Metastasis-Free Survival (MFS)
MFS is defined as the time from the date of first treatment initiation for HR-NMIBC to the occurrence of distant metastasis, death from any cause, or censoring, whichever occurs first.
Time frame: Up to 5 years
Time to Next Treatment (TTNT)
TTNT is defined as the time from the date of first treatment initiation for HR-NMIBC to the initiation of the next line of treatment or censoring.
Time frame: Up to 5 years
Time on Treatment (TOT)
TOT is defined as the duration between the first and last administration of the treatment.
Time frame: Up to 5 years
Complete Response Rate (CR)
Complete response is defined as the absence of detectable bladder cancer at 6 months after completion of treatment, as confirmed by cystoscopic evaluation and optionally complemented by urine cytology.
Time frame: Up to 5 years
Number and Type of Healthcare Resource Utilization Related to HR-NMIBC
Number and type of healthcare resource utilization related to HR-NMIBC, including procedures, hospitalizations and outpatient visits will be reported.
Time frame: Up to 5 years
Plan to share: Yes — The data sharing policy of Johnson \& Johnson Innovative Medicine is available at https://www.jnj.com/innovativemedicine/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.
Data sharing details ↗ · www.jnj.com
No publications or documents are linked to this record.
Started Aug 2026 (actual). Primary completion is estimated for Feb 2028, 17 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Janssen-Cilag Farmaceutica Ltda. →